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INTERNATIONAL PERSPECTIVES ON PHARMACY PRACTICE
Roles of Hospital and Territorial Pharmacists
within the Italian National Healthcare Service
Piera Polidori, Carlo Cifani, and Carlo Polidori
INTRODUCTION
The central body of the Italian National Healthcare Service(NHS) is the Ministry of Health, which coordinates the
NHS and is responsible for government functions related to
health care for Italy’s 60 million inhabitants.
The Ministry of Health works in collaboration with the
governments of the 20 Italian regions, 15 of which operate
under a “normal” statute and 5 under a “special” statute. The
NHS develops a National Healthcare Plan (Piano Sanitario
Nazionale), proposed by the Ministry of Health, which then 
is put into effect by the government, keeping in mind the 
proposals made by the individual regions. This 3-year plan 
indicates the priority areas where work is needed to reduce 
social inequalities in health care. It is used to define general 
objectives and methods for carrying out the institutional 
activities of the NHS. The National Healthcare Plan stipulates
various essential levels of assistance (Livelli Essenziali di Assis-
tenza or LEAs), which represent guarantees of the objective of
social equality among all citizens and which are necessary to
meet the fundamental needs of promotion, maintenance, and
recovery of health; the Plan also establishes the modalities for
meeting these goals. The LEAs are the activities and services
that the NHS is bound to guarantee for all citizens, free of
charge or with copayment, by collecting funds through the 
taxation system. At the regional level, the regions follow a 
3-year Regional Healthcare Plan (Piano Sanitario Regionale) for
putting the NHS plan into action, taking into consideration
both national and regional objectives.
The Italian NHS offers universal assistance, that is, medical
treatment to all those who need it. To guarantee the sustain-
ability of such a system, considering the increasing cost of 
innovative medicines and medical devices, all of the health care
professionals involved must take great care to monitor the 
appropriateness of diagnostic and treatment plans to ensure that
the measures taken correspond to patients’ needs, according to
the correct instructions for medicines, in terms of efficacy for
a specific pathology; these measures must be provided in 
suitable ways and within adequate times, on the basis of 
recognized standards, with a positive balance between benefits,
risks, and costs.1
The NHS carries out its functions through the 20 regional
governments, by means of hospital firms (Aziende Ospedaliere)
and health care firms (Aziende Sanitarie), each health care firm
being an administrative aggregation of more than 2 hospitals.
Through these hospital and health care firms, the NHS 
provides most of the health care assistance in Italy, with the 
remainder being provided by private structures that operate
through an agreement with the national system.
In this context, the NHS pharmacists play a crucial role,
inasmuch as Italy has 2 distinct, but well-integrated types of
pharmacist, the first working in hospital pharmacies and the
second, known as territorial pharmacists, working in the 
pharmaceutical services of the local or provincial health care
firms. These 2 types of pharmacists work together with other
health care professionals as members of treatment commissions
or multidisciplinary work groups to evaluate the use of 
medicines according to appropriateness criteria based on current
legislation, scientific evidence, and economic evaluations. 
An overview of the total number of pharmacists and the
workload for hospital pharmacists appears in Table 1.2
Hospital pharmacists also formulate shared Diagnostic and
Treatment Itineraries of Assistance. For this, they consider not
only medicines but also clinical practice, examining all 
aspects of the pharmacological treatment of individual patients
and taking into account the patients’ specific and particular
characteristics. As such, these pharmacists contribute to the 
personalization of treatment and support specialists in 
optimization of that treatment. 
In addition to the 2 types of pharmacist described above,
Italy also has community pharmacists, whose important 
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contributing role is not part of the NHS, but who work
through an agreement with the NHS. Their total number in
Italy is about 50 000, and they work in community pharmacies
that are open to all citizens. They distribute prescription and
over-the-counter drugs and prepare compounded drugs, 
working under a for-profit model. In addition, they are 
involved in pharmacovigilance, health-related education, and
health promotion.
The NHS pharmacists guarantee the quality of pharma-
ceutical assistance and the correct balance between appropri-
ateness, quality, and costs, especially through continual
monitoring of the appropriate use of drugs and medical devices. 
TASKS OF THE HOSPITAL PHARMACIST
In the United States and some European countries, hospital
pharmacists have for years carried out much of their activity in
hospital wards, alongside physicians and nurses, on increasingly
specialized and multidisciplinary teams.
In Italy, some experiences of this kind have been described,
especially in oncology and antimicrobial stewardship, but the
model of the hospital ward or department pharmacist has 
yet to become widespread. Conversely, hospital pharmacists 
intervene on a daily basis in assessing the appropriateness of
prescriptions, assessing the quality of pharmaceutical assistance,
and controlling expenditures, in full collaboration with the
other operative units and services involved in the process of
pharmaceutical therapy in the hospital setting.3-5
Hospital pharmacists are active on numerous commissions
of their health care firms, for example, those concerned with
infections, treatments, or health technology assessment. In this
capacity, they help in making decisions about the appropriate
use of medicines and medical devices, and in choosing which
medicines and medical devices should be purchased according
to criteria of appropriateness, in line with current legislation
and guidelines.6
In addition, in dispensing medications for patients who
are in the first cycle of treatment (called “direct distribution”
[distribuzione diretta]) or for those who travel from one Italian
region to another for treatment, hospital pharmacists are 
particularly active in guaranteeing appropriateness and 
adherence with current legislation. In this context, they provide
information to patients for home treatment, underlining the
importance of compliance with the physician’s prescriptions
and instructions. The hospital pharmacist is also involved in
medication reconciliation when patients are admitted, during
their hospital stay, and when they are discharged. For example,
in the main hospital in the Marche Region, which has 1000
beds, hospital pharmacists examine pharmacological treatment
plans for patients, and every month propose modifications for
an average of 600 drug treatment plans, most of which are 
related to cancer and cardiology treatments; at this hospital,
each treatment plan is managed by 2 hospital pharmacists.
Another important role for hospital pharmacists is serving
as members of the Ethics Commission of their respective health
Table 1. Number of Pharmacists in Italy and Number of Beds Served by Each Hospital Pharmacist*
                                                           No. of Pharmacists                                                               Total                        
                                                                                                                          Beds/1000          Population             No. of 
Region                              Total†               Territorial              Hospital          Population           (millions)             Beds/HP
Abruzzo-Molise                 65                     18                     47                    3.9                     1.6                   132
Apulia                             175                     52                   123                    3.5                     4.1                   117
Basilicata                           25                       8                     17                    3.7                     0.6                   131
Calabria                          104                     47                     57                    3.7                     1.9                   123
Campania                       300                     90                   210                    3.3                     5.8                     91
Emilia - Romagna            175                     48                   127                    3.2                     4.4                   111
Friuli Venezia Giulia            62                     15                     47                    4.1                     1.2                   105
Lazio                               208                     55                   153                    4.2                     5.8                   159
Liguria                               99                     20                     79                    4.3                     1.6                     87
Lombardy                        341                     69                   272                    4.1                   10.0                   151
Marche                             91                     21                     70                    3.9                     1.5                     84
Piedmont                        263                     62                   201                    4.7                     4.5                   105
Aosta Valley                        
Sardinia                           121                     44                     77                    3.9                     1.6                     81
Sicily                                307                     83                   224                    3.4                     5.1                     77
Tuscany                           158                     42                   116                    3.8                     3.7                   121
Trentino South Tyrol            21                       4                     17                    4.2                     1.0                   247
Umbria                              46                     12                     34                    3.6                     0.9                     95
Veneto                            152                     40                   112                    3.9                     4.9                   171
Total                              2713                   730                 1983                    NA                  60.2                    NA
HP = hospital pharmacist, NA = not applicable.
*Based on data for 2013, published in Personale delle A.S.L. e degli Istituti di ricovero 
pubblici ed equiparati Anno 2013.2
†Sum of territorial pharmacists and hospital pharmacists.
This single copy is for your personal, non-commercial use only.
For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at publications@cshp.ca
311CJHP – Vol. 70, No. 4 – July–August 2017 JCPH – Vol. 70, no 4 – juillet–août 2017
care firms. In this role, they often run the scientific secretariat
of the Commission and serve in the office that reports on 
clinical trials conducted at the hospital. In addition, hospital
pharmacists are increasingly active in clinical trials, sometimes
as principal investigators. Hospital pharmacists are also 
responsible for managing experimental medicines during 
clinical trials. In the case of parenteral administration, it is 
the hospital pharmacist’s duty to prepare the experimental
drugs for administration.
In some health care firms, the hospital pharmacies have
hazardous drug compounding laboratories where anticancer
drugs are diluted into infusion bags. In these firms, this 
important service is provided by hospital pharmacists, who 
follow national guidelines developed by the Italian Society of
Hospital and Territorial Pharmacists (Società Italiana di 
Farmacia Ospedaliera e dei Servizi Farmaceutici delle 
Aziende Sanitarie, known as SIFO) to ensure the quality of 
compounded drugs. For example, in the main hospital of the
Marche Region, 3 full-time pharmacists prepare, with the help
of a robot, about 25 000 oncology infusion bags a year. Other
duties of the hospital pharmacist are the formulation or set-up
of personalized preparations for individual patients, including
bags for total parenteral nutrition, specific arrangements for
drugs not available on the market and required for treatment
of rare diseases, and preparation of unit doses of drugs. A 2005
study7 reported that hospital pharmacists in the 9 major Italian
hospitals for pediatric patients made ready about 100 000 
personalized preparations for pediatric patients or premature
newborns. Finally, hospital pharmacists are involved in quality
control of the radiopharmaceuticals used in the hospital. 
In the sphere of oncology, hospital pharmacists are respon -
sible for writing, codifying, and updating treatment protocols
proposed by clinicians, checking to ensure that they correspond
to the criteria of scientific and legislative appropriateness. In
addition, for each individual patient, hospital pharmacists
check that the approved treatment plans are properly applied,
for example, in terms of instructions for use, dosage, posology,
infusion time, and dilution solvents. Hospital pharmacists 
are also responsible for ensuring quality during set-up and 
administration, by analyzing processes and writing procedures
and instructions to reduce risk. Because examination of the 
appropriateness of prescriptions is specifically a duty of hospital
pharmacists, these health care providers have been integrated
into the Italian Medicine Agency (Agenzia Italiana del 
Farmaco) system for drug monitoring via online registers. In
general, they monitor the use of all drugs administered in the
hospital, in terms of consumption and expense, as well as in
terms of the individual patient (e.g., if drugs are to be admin-
istered in a particular way for treatment of a given patient),
with specific attention to indicators of appropriateness detailed
at the regional or national level. The number of times that the
online register is accessed varies with the number of beds in
each hospital. For example, in a hospital of 300 beds, the 
register was accessed on average 30 times a month to request
reimbursement of hospital expenses incurred in dispensing 
oncology drugs and about 300 times a month to register the
unit doses of special drugs delivered. 
Hospital pharmacists engage in intense activity of forma-
tion (producing evidence about drug-related activity and 
medical device efficiency) and information (collecting data)
about medicines and medical devices. Some hospitals have 
a formal centre that supports physicians and nurses with 
information about drugs, for example, regarding dosages, 
indications, contraindications, or any particular information
requested. 
Finally, hospital pharmacists make an important contribution
to pharmacovigilance and medical device vigilance, monitoring
of drug interactions, and management of clinical risk. For years,
national and regional health care policies have sought to reduce
clinical risk, especially in the management of drugs, as demon-
strated by the publication of recommendation 7 of the Ministry
of Health (“Recommendations for the prevention of death,
coma or grave harm caused by errors in pharmaceutical treat-
ment: an incorrect use of drugs can cause adverse events with
grave consequences for the patient”) and by subsequent recom-
mendations 12, 14, and 17.8 This is surely a sphere in which
ongoing work must be done to optimize strategies for reducing
and preventing errors.8
One other important function of the hospital pharmacist
is to develop the hospital budget for drugs and medical devices
and to ensure that the hospital adheres to it.
Finally, in some health care firms, hospital pharmacists are
involved in the process of obtaining Ministry of Health quality
accreditation for the daily activities of the hospital pharmacy.
This is accomplished by reporting that all of the technological
and organizational processes required by the International Joint
Commission or by the International Organization for 
Standardization are present in the hospital’s pharmacy. 
TASKS OF THE TERRITORIAL PHARMACIST
The second type of pharmacist involved in hospital work,
with the same employment contract as a hospital pharmacist
but having different activities, is the territorial pharmacist (a
role that is distinct from that of the community pharmacist).
To our knowledge, the territorial pharmacist is exclusive to the
Italian NHS, with no counterpart in other European Union
countries, the United States, or other nations. Like the hospital
pharmacist, the territorial pharmacist plays a key role within
Italian local health authorities in enhancing the appropriateness
of prescriptions. The territorial pharmacist distributes specific
drugs that are prescribed by hospital physicians but are 
not available in the community pharmacy, such as growth 
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hormones, antiemetics, and monoclonal antibodies, at selling
prices determined by the hospital. This distribution is called
“direct distribution” (distribuzione diretta), and the service takes
place in the pharmacy of the hospital or in a different building.
The drugs distributed by the territorial pharmacist are under
the strict control of the Italian Medicine Agency. During the
period January to August 2016, total direct 
distribution sales in Italy were about 3.7 billion euros for class
A drugs (essential drugs for chronic conditions, which are 
distributed by the NHS at no cost to patients). Several studies
conducted by hospital pharmacists have demonstrated that 
the expertise of hospital and territorial pharmacists reduced 
the total cost of drugs that the NHS provides to the Italian 
population by about 20%.9
Another activity of territorial pharmacists is the provision
of pharmaceutical service’s, which involves examining prescrip-
tion data from community pharmacies that have agreements
with the NHS, through which community pharmacists distribute
drugs for the hospital at selling prices determined by the 
hospital. This drug management system is called “distribution
on behalf of the local health care firm” (distribuzione per 
conto). For example, for the year 2016 in the Marche Region
(population 307 000), 3 million filled prescriptions were
checked by 4 full-time territorial pharmacists. For the most
part, the data collected are related to patients with diabetes, 
arterial hypertension, osteoporosis, or other chronic conditions.
One difficulty that territorial pharmacists encounter in exam-
ining prescription data from community pharmacies is that the
reports do not indicate the diagnosis, except in cases where 
the patient has taken measures to obtain an exemption from 
copayment because of an ongoing condition; in that situation,
the physician indicates the “exemption due to pathology” code
on the prescription. This lack of information about the 
diagnosis makes it difficult to ascertain whether the dosage,
posology, and length of treatment are appropriate.
In an effort to optimize appropriateness of prescriptions,
territorial pharmacists send reports to general practitioners
(Medico di Medicina Generale) and to pediatricians (Pediatra 
di Libera Scelta) comparing the number of their prescriptions
with those of other professionals regionally and nationally. 
They also organize meetings to address problems such as 
overprescribing and to improve the services provided by these
2 types of health care professionals. 
Territorial pharmacists may also serve as members of the
boards of directors of the local health care firms or as represen-
tatives to medical organizations, analyzing reports on pharma-
ceutical prescriptions in their specific districts. These reports
detail gross per capita expenditure on class A drugs (which are
paid entirely by the Italian NHS) that have been dispensed by
community pharmacies and highlight how these expenditures
differ from regional and national averages for total consump-
tion, according to the Anatomical Therapeutic Chemical
(ATC) classification of drugs, in terms of defined daily 
dose (DDD) per 1000 inhabitants and expenditure per 1000
inhabitants.
Another set of parameters analyzed by the board of each
local health care firm are the expenditure and DDD for generic
drugs relative to the total number of prescriptions. The board
monitors the quality of the drugs (according to ATC classifica-
tion, brand name, generic name, etc.) and the quantity (posology,
length of treatment, and compliance with treatment), with 
attention to spending limits for each ATC class, in cases where
these limits have been established by regional legislative decrees.
On a regular basis, the board analyzes the reports, identifies
problem areas, and decides what actions to take and for which
categories of drugs. Each health care firm may choose the 
actions it deems most useful, for example, promoting the 
presence of generic drugs on the market (when existing use of
generic products is too limited) or focusing on categories 
of drugs with consumption that exceeds regional and national
averages in terms of DDD per 1000 inhabitants or average per
capita expenditure.
Once the board has examined the prescription reports, it
works to inform and educate physicians to resolve the problems
that have emerged. Specific meetings and courses are organized
in the districts, during which the territorial pharmacist 
describes the consumption data for the drug class in question,
explains the approved instructions for use, illustrates cost 
comparisons for the various active ingredients, and communi-
cates the problem areas identified during monitoring, including
treatment switches and compliance with treatment instructions.
In most districts in Italy, these meetings take place 6 times a
year. The general practitioners and/or pediatricians at each
gathering bring their experience to bear on the discussion by
presenting clinical cases. Starting from the diagnosis of a given
condition, the guidelines and protocols for diagnosis and treat-
ment are examined and the efficacy of the drug is discussed,
particularly whether it is effective in terms of clinical end points
(i.e., not just in the laboratory). There is also in-depth 
discussion of cases in which the patient presents with factors
that could heighten or reduce the drug’s effect or that 
predispose the patient to adverse events.6 The discussion also
covers the correct dose, whether the posology prescribed is 
simple for the patient to follow, the instructions that should 
be given to facilitate consumption of the drug, potential 
interactions with other drug categories or with foods, manage-
ment of adverse events, the appropriate duration of treatment
for each condition, and finally which treatment costs the least,
with equivalent effectiveness.
Territorial pharmacists are indispensable for the monitoring
and analysis of treatments, bringing their specialized knowledge
and skills to these meetings and courses. They also prepare a
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final document for the physicians to explore aspects of treating
a given condition and the appropriate use of drugs. Their 
activities ensure that the information provided is independent
and correct, which may not always be the case when physicians
rely exclusively on explanations provided by pharmaceutical
firms. 
In the case of some categories of drugs that patients often
buy without a prescription, the board may decide to organize
campaigns to educate the public about indications, contraindi-
cations, and side effects in the case of inappropriate use. The
territorial pharmacist then prepares pamphlets to distribute to
the public and educational posters for doctors’ waiting rooms. 
Following these activities, the board may evaluate the 
results achieved in terms of appropriateness of prescriptions by
comparing clinical data against predefined standards, such 
as prescriptions exceeding regional and national averages, pre-
scriptions for drugs not considered to be the first choice for a
particular condition, and percentage of generic drugs out of the
total number of prescriptions for a given category. Wherever
this model has been applied, the results have been increased
awareness among physicians and reduced expenditures for
drugs. 
Another important service provided by territorial pharma-
cists involves reconciliation of prescriptions and treatments for
patients who transition from one care setting to another, for
example, patients discharged from a hospital ward who go on
to an assisted health care residence or patients with a terminal
illness who leave their homes for hospice. Many of these 
patients are taking a number of drugs, and it is important to
be alert to potential drug interactions and/or adverse drug 
reactions. Considerable attention must be devoted to delivery
of medical devices for patients who have undergone gastro -
stomy, urostomy, or tracheotomy; patients with bedsores; and
those who have a catheter. In these cases as well, monitoring is
required to ensure that the device is appropriate for the patient’s
condition and that there is compliance by the patient or 
caregiver. 
Finally, territorial pharmacists inspect community 
pharmacies to ensure they comply with Italian laws regulating
organization and technical equipment, as well as those regarding
the management and disposal of narcotics.
EDUCATIONAL REQUIREMENTS FOR 
HOSPITAL AND TERRITORIAL PHARMACISTS
In the mid-1990s, Italian universities established schools
of specialization in the pharmaceutical field, called “schools of
specialization in hospital pharmacy”. Since then, to attain access
to such a school, students must first complete a 5-year pharmacy
program in any Italian or foreign university. Then, after passing
the board certification test, they must pass another selection
test (in pharmacology, pharmaceutical chemistry, and 
compounding) at a university where this postgraduate program
is offered. Indeed, not all schools of pharmacy have started the
program, and today only 21 of the 24 Italian schools of 
pharmacy have a program of specialization in hospital 
pharmacy (and of these, not all are currently running). 
In response to innovations that pharmaceutical firms have
been implementing with hospitals to improve the quality of 
patient care and changes in the pharmacist’s role in this setting,
pharmacy faculty members realized that a typical 5-year course
of pharmacy was no longer sufficient preparation for work in
hospital pharmacies, and decided that at least 2 further years
of specialization were needed. A few years later, in 1995, Italian
universities reached an agreement that the academic program
for such a “school of specialization in hospital pharmacy”
should last at least 3 years. This process of recognizing the need
to expand training to encompass new issues emerged through
contact between experienced pharmacists who had been working
in hospital settings for several years and professors teaching in
faculties of pharmacy. This new degree program of specialization
has led to a variety of new courses, such as pharmacokinetics,
radiotherapy, and hospital and health organization in Italy.
Practice in the hospital setting became a mandatory part of 
the program. During their hospital internship, students gain
practical experience with such tasks as preparing bags for 
anticancer drug infusions, defining diets for underweight 
newborns, and other administrative duties, including ordering
drugs from manufacturers. The time devoted to this practical work
at the hospital pharmacy was set at about 500 hours per year.
In the meantime, through law 509, the Italian Ministry
for Education and Research introduced the concept of “credits”
in November 1999, defining a credit as 25 hours of study for 
a university student, and specifying that a student must earn 
60 credits each year. Therefore, to earn a bachelor degree in
pharmacy, a student had to obtain 300 credits over 5 years of
education. This concept of credits was then extended to the
higher education program of specialization. Indeed, the 2005
law defined for each area the maximum number of credits 
required to prepare a student in the field of hospital pharmacy.
For example, the core number of credits for this specialization
was 195 out of the 300 total credits, including pharmacology
and pharmaceutical compounding.
The 2005 law concerned the reorganization of all kinds of
schools of specialization in the health system, including the 
hospital pharmacy degree program, adding an academic year
to the previous 3-year program. This new 4-year program 
introduced classes on pharmacovigilance, hospital bioethics,
health technology assessment, and Italian legislation for the 
approval of medical devices. 
The most impressive development arising from the new
law in 2005 was the change in the number of students allowed
to attend these programs, calculated in relation to the turnover
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of hospital pharmacists in the Italian health system. The total
number of students was set at 150 for the entire country, with
an average of 8 students per school being eligible. Thus the only
criterion was the need to replace those who retired or changed
fields, to maintain equilibrium in the health care system. 
An important factor was introduced with a new law in
2006, concerning the general organization of schools of 
specialization in the health system. Each school had to demon-
strate to the government that its students did their practical
work in multiple hospitals. To this end, the Italian Ministry of
Education and Research organized an online national database
where the directors of the schools of specialization in hospital
pharmacy could record the names of the hospitals involved in
student training for their respective programs. 
As mentioned above, the teaching program for specialization
in hospital pharmacy, based upon the 2005 law, is organized
into 4 academic years, with 30% of the total credits earned
through courses and the remaining 70% through hospital training
within the school’s network. 
For the 30% of the program devoted to coursework at the
university, the program contains 4 or 5 courses per year. 
Student evaluations have indicated that the first-year courses
in pathology and biostatistics are the most appreciated, whereas
in the second year pharmacokinetics and nutrition courses 
receive positive feedback. In the third year, students have found
most interesting their courses in radiopharmacy and clinical
pharmacology. In the final year, courses about clinical pharma-
cology and management of the hospital setting have been
viewed as the most innovative.  
For the 70% of the program based on in-hospital training,
the Italian Society of Hospital and Territorial Pharmacists 
prepared a document that was distributed to all universities
with the degree program in hospital pharmacy and to all 
hospital pharmacy directors of each school’s hospital network.
This document was essentially a copy of the pertinent law 
concerning practical training, but it also detailed all of the 
practical skills that students should master during their training,
indicating the order in which these skills should be developed
throughout the 4 years of the program.
The law of 2015 (Decreto Interministeriale 68, dated 
February 4, 2015) makes it clear that students must do more
hours of training. It is to be hoped that through this additional
training time, the students will gain more clinical experience.
In most European countries, hospital pharmacists do rounds
with clinicians, suggesting and in some cases prescribing, 
together with the physician, the best drug for each patient, at
the patient’s bedside. In Italy, however, clinical pharmacists have
had little experience of this type in recent years; when such 
experience has occurred, it has been prompted primarily by 
a physician’s simple request for the hospital pharmacist’s 
collaboration. Given their extensive knowledge about drugs,
hospital pharmacists should be collaborating with clinicians,
drawing upon scientific data and evidence-based medicine data.
In this context, the hospital pharmacist could give the physician
great help in managing risks due to drug use in the clinical 
setting. In fact, the Italian NHS has just published a recom-
mendation on how the hospital pharmacist and other health
care professionals should develop processes for safety in health
care to reduce therapeutic errors. 
Since the mid-1990s, efforts to develop better schools of
specialization have been ongoing. Credit for this improvement
is surely due to the strong interaction between scientific 
societies and universities. Three main things must merge 
harmoniously to promote better-quality health care and 
harmonious growth of the system: people, knowledge, and 
resources.
CONCLUSION
The organization of the Italian NHS is complex, but the
system is founded on principles of universality and equality.
Monitoring the appropriateness of prescriptions is a valid 
approach for all regions of the country, but above all for those
that are under a specific management regime to bring 
expenditures back to budgeted levels and to govern the efficacy,
efficiency, and costs of drugs and health care in general.
The training and skills of hospital pharmacists and 
territorial pharmacists, which include not only specialist skills
in pharmacology, but also managerial abilities, are indispensable
for optimizing the decision-making processes for selection and
prescription of therapeutic drugs, diagnostic drugs, and medical
devices.
It is evident that pharmacists carry out their activities with
constant attention to the health needs of citizens, by educating
patients about the correct use of drugs that are prescribed and
by ensuring the quality, efficacy, and safety of the products 
prepared and distributed, without neglecting the pharmacological
and cost aspects related to their use.
For this reason, it is fundamental that university under-
graduate and graduate programs continually update their 
offerings, with active contributions from the country’s scientific
community, especially the Italian Society of Hospital and 
Territorial Pharmacists, to meet the ever-growing and changing
needs dictated by daily work in hospital and territorial 
pharmaceutical structures.
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